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Background 
Scarce data are available to guide cefazolin dosing in children undergoing 
cardiac surgery with cardiopulmonary bypass (CPB).  
Objectives 
Intermediate results 
The objective of this trial is to derive a model-based dosing regimen for 
cefazolin in this patient population. 
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Methods 
• 56 infants and children were included and received following intravenous dosing regimen: 25 mg/kg as a bolus 30 minutes before surgical incision, just 
before cessation of CPB, 8 hours after the 2nd dose and 8 hours after the 3rd dose.  
• Blood samples were collected before, during and after cardiopulmonary bypass. Total (n=497) and unbound cefazolin concentrations (n=494) were 
measured using a validated High-Pressure Liquid Chromatography method; unbound concentrations were separated using a validated ultrafiltration 
method. 
• NONMEM® version 7.2 was used for population PK modeling and covariate analysis: one, two and three compartmental models with first-order elimination 
were evaluated. R®, PsN® and Xpose® tools were used for data manipulation, graphical and statistical summaries. 
• Glomerular Filtration Rates (eGFR) pre-, on- and post-CPB were estimated using the Modified Schwartz formula.  
• Internal validation of the final model was performed using a non-parametric bootstrap (n=500 samples), a prediction corrected Visual Predictive Check 
(pcVPC) (n=1000 simulations) and the Normalised Prediction Distribution Error method (NPDE)(n=1000 simulations). 
• To evaluate the current dosing regimen, Monte Carlo simulations (n=1000 simulations) were performed for a typical patient, procedure duration and 
median eGFR during the pre-, on- and post-CPB period. A minimum time frame of 60% of the dosing interval in which the unbound drug concentration 
remained above the Minimal Inhibitory Concentration (MIC) of Staphylococcus aureus (8 mg/L) was aimed for. 
Discussion and Perspectives 
• The proposed model adequately describes bound and unbound plasma cefazolin pharmacokinetics in infants and children undergoing cardiac surgery with 
cardiopulmonary bypass. 
• Based on Monte Carlo simulations, the current dosing regimen needs to be optimised with a maximum dosing interval of 5-6h in postoperative patients. 
• In a next step, a tissue concentration pharmacokinetic model will be developed to investigate the adequacy of dosing in terms of tissue penetration. 
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Fixed effects 
𝐶𝐿𝑖,𝑢𝑛𝑏𝑜𝑢𝑛𝑑 = 𝐶𝐿𝑝𝑜𝑝 ×  
𝑊𝑇
𝑊𝑇𝑚𝑒𝑑
0.75
×
𝑒𝐺𝐹𝑅
6.48
  
CL (L/h) 1.8 5 1.81 1.64 1.97 
𝑄𝑖,𝑢𝑛𝑏𝑜𝑢𝑛𝑑 = 𝑄𝑝𝑜𝑝 ×  
𝑊𝑇
𝑊𝑇𝑚𝑒𝑑𝑖𝑎𝑛
0.75
 
Q1 (L/h) 4.79 6 4.84 4.24 5.45 
Q2 (L/h) FIXED to cardiac output during CPB 
𝑉𝑖,𝑢𝑛𝑏𝑜𝑢𝑛𝑑 = 𝑉𝑝𝑜𝑝 ×  
𝑊𝑇
𝑊𝑇𝑚𝑒𝑑𝑖𝑎𝑛
1
 
V1 (L) 1.87 6 1.88 1.63 2.10 
V2 (L) 2.29 7 2.32 2.02 2.64 
V3 (L) FIXED to CPB priming solution volume 
𝐵𝑚𝑎𝑥 = (𝜃𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡  + 𝜃𝑠𝑙𝑜𝑝𝑒  × 𝑎𝑙𝑏𝑢𝑚𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛) 
𝜃𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 (mg/L) 132 13 133 98 169 
𝜃𝑠𝑙𝑜𝑝𝑒  1.60 21 1.64 1.11 2.20 
KD (mg/L) 47.7 10 48.5 40.3 59.2 
Interindividual variability 
Ѡ2 CL 0.095 28 0.088 0.046 0.15 
Ѡ2 V1  0.111 38 0.107 0.039 0.188 
Ѡ2  V2 0.241 25 0.232 0.116 0.365 
Ѡ2 Bmax 0.043 38 0.040 0.016 0.074 
Residual variability (proportional) 
σ2 (unbound 
concentration) 
0.074 11 0.073 0.056 0.091 
σ2 (total 
concentration) 
 
0.026 16 0.025 0.017 0.034 
PATIENT CHARACTERISTIC 
  
MEDIAN (RANGE) 
  
Age (days) 270 (5-5439) 
Weight (kg) 6.8 (2.7-70) 
Procedure duration (h) 2.15 (1.21-8.50) 
CPB duration (h) 1.30 (0.37-5.1) 
eGFR (mL/min/1.73 m2) pre CPB 108 (32-187) 
eGFR (mL/min/1.73 m2) during CPB 80 (29-112) 
eGFR (mL/min/1.73 m2) post CPB 74 (27-135) 
Cardiac output (L/h) during CPB 44.82 (18.36-249) 
Albumin (g/dL) 36 (21.8 -53) 
Priming volume (mL) 175 (150-1000) 
 
Table 1. Patient characteristics 
Figure 1 : Structure of the final model 
Table 2. Parameter estimates (1 273 successful runs) 
Figure 4. Prediction-corrected Visual Predictive Check (n=1000) (left: panel unbound; right panel: total concentrations)  
 
               Legend: dots: observations; solid  red line: observed median; dashed red lines: observed 5th and 95th percentiles;  
                    shaded areas : 95% CI of  simulated 5th, 50th and  95th percentiles 
Figure 5. Monte Carlo simulations for a typical patient, procedure duration and median eGFR  pre-,on- and post CPB 
                   
                 Legend : solid line: median ; dotted lines : 5th and 95th percentiles (n= 1000); red dashed line: MIC cut-off 
Figure 2 : Goodness-of-fit plots and  distribution  histogram of NPDE for unbound concentrations 
Figure 3: Goodness-of-fit plots and  distribution histogram of NPDE for total concentrations 
